ABH Cream Dosing
ABH cream (lorazepam, diphenhydramine, and haloperidol gel) should not be used, as high-quality evidence demonstrates it is ineffective—the active ingredients are not absorbed through the skin at therapeutic levels and performs no better than placebo.
Why ABH Gel Does Not Work
The most definitive evidence comes from rigorous pharmacokinetic and clinical studies:
No drug absorption: A 2012 study using liquid chromatography-tandem mass spectrometry found that lorazepam and haloperidol were completely undetectable in blood samples after topical application of standard 1.0 mL doses. Diphenhydramine showed only erratic, subtherapeutic absorption (maximum 0.30 ng/mL) 1.
No clinical benefit: A 2014 randomized, double-blind, placebo-controlled crossover trial in cancer patients with nausea found ABH gel was noninferior to placebo. The mean nausea reduction was 1.7 points with ABH gel versus 0.9 points with placebo (p=0.42), with no difference in vomiting episodes 2.
Cochrane review confirmation: A 2015 systematic review concluded there is insufficient evidence from RCTs to support haloperidol (a key ABH component) for nausea/vomiting in palliative care, and specifically noted that topical haloperidol is not significantly absorbed 3.
What to Use Instead
For the conditions ABH gel is commonly prescribed:
For Acute Agitation (Emergency/Inpatient Settings):
- Avoid diphenhydramine entirely in older adults due to strong anticholinergic properties that should be avoided per geriatric guidelines 4
- Haloperidol + lorazepam combination ("52") is more effective than adding diphenhydramine:
For Nausea/Vomiting in Palliative Care:
- Oral or parenteral haloperidol: 0.5-2 mg orally 2-3 times daily for moderate symptoms 5
- Oral or parenteral lorazepam: 1-2 mg orally 2-3 times daily 6
- Alternative antiemetics with proven efficacy (metoclopramide, ondansetron, olanzapine)
Critical Pitfalls to Avoid
- Do not prescribe ABH gel based on anecdotal reports or perceived efficacy—this represents placebo effect and delays effective treatment 8
- Parenteral formulations are superior to oral: IV/IM routes showed significantly higher adverse event rates but faster onset compared to oral (OR 10.17 for IV vs oral) 4
- Avoid droperidol combinations despite historical use, given FDA black box warning, though some evidence suggests safety concerns may be overstated 9
The Bottom Line
ABH gel continues to be prescribed in hospice/palliative care despite definitive evidence of inefficacy. A 2023 study exploring ABH Carbopol gel (different formulation) showed improved absorption compared to the standard PLO gel, but estimated steady-state concentrations remained subtherapeutic 10. Use proven oral or parenteral formulations of these medications individually or in combination, dosed according to FDA labeling, rather than compounded topical preparations.